Near-clinical-stage developer of small-molecule modulators targeting 7‑transmembrane GPCRs to treat chronic and fibrotic diseases, including idiopathic pulmonary fibrosis. Focuses on modulating fibroaging and inflammaging pathways to deliver potent therapeutics for unmet medical needs.